Approvals In Brief
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Abbott’s Humira gains ankylosing spondylitis claim, putting agent in closer competition with Amgen’s Enbrel and Johnson & Johnson/Centocor’s Remicade. Shire’s Elaprase (idursulfase) is first enzyme replacement therapy approved for Hunter syndrome. More approvals in brief